A Phase IIb Trial of a Novel Extended ‐Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis

ConclusionAlthough the primary end point was not met, our findings indicate a prolonged reduction in symptoms with FX006 with an evident dose response and a safety profile similar to saline placebo.

Source: Arthritis and Rheumatism - December 20, 2017 Category: Rheumatology Authors: Philip G. Conaghan, Stanley B. Cohen, Francis Berenbaum, Joelle Lufkin, James R. Johnson, Neil Bodick Tags: Brief Report Source Type: research